Subscribe
Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

JAMA Editor’s Summary

Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

Editors’ Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the
January 3, 2017
ADVERTISEMENT
DOCSF21

Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

Editors’ Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the January 3, 2017 issue

ADVERTISEMENT
DOCSF21

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

HealthXLGet Health
cover
Javier Lozano - Market-Creating Innovation for Diabetes Care an inspiring conversation with Javier Lozano, Founder and CEO of Clínicas del Azúcar, a growing chain of "one-stop shops" for diabetes care in Mexico.